|
|
|
|
| LEADER |
01501nam a2200241 u 4500 |
| 001 |
EB002002074 |
| 003 |
EBX01000000000000001164975 |
| 005 |
00000000000000.0 |
| 007 |
tu||||||||||||||||||||| |
| 008 |
210907 r ||| eng |
| 100 |
1 |
|
|a Carson, Susan
|
| 245 |
0 |
0 |
|a Drug class review on newer drugs for insomnia
|h Elektronische Ressource
|b final report
|c Susan Carson, Po-Yin Yen, Marian S. McDonagh
|
| 260 |
|
|
|a Portland, Or.
|b Oregon Health & Science University, Evidence-Based Practice Center
|c 2006, c2006
|
| 300 |
|
|
|a PDF file (90 p.)
|
| 505 |
0 |
|
|a Includes bibliographical references
|
| 710 |
2 |
|
|a Oregon Health & Science University
|b Evidence-based Practice Center
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b NCBI
|a National Center for Biotechnology Information
|
| 490 |
0 |
|
|a Drug class reviews
|
| 500 |
|
|
|a "July 2006."
|
| 856 |
4 |
0 |
|u https://www.ncbi.nlm.nih.gov/books/NBK10549
|3 Volltext
|
| 082 |
0 |
|
|a 610
|
| 520 |
|
|
|a Insomnia is a serious health problem that affects millions of people. Treatment involves behavioral changes, such as minimizing daily habits that interfere with sleep, and pharmacotherapy. The newer drugs for insomnia differ from each other in their pharmacokinetics, which could be expected to affect different aspects of insomnia. For example, drugs with a shorter half-life might be effective for sleep latency but less effective for sleep duration. The purpose of this review is to compare the effectiveness and harms of these newer drugs for treatment of insomnia
|